Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
D000293:Adolescent; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000276:immunology; D007223:Infant; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016305:Thymopentin; D013946:Thymopoietins / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*; D013997:Time Factors
D006728:Hormones; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin